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Objectives
Given :
• the natural genetic polymorphism of HIV-1/O
• limited data on II efficacy in vivo and in vitro,
we aimed to determine the natural
susceptibility of HIV-1/O clinical isolates
to RAL, EVG and DTG in a phenotypic
assay by measuring the concentration of
drugs that inhibits 50% of viral inocula (IC50).
Material & Methods
Results   (table 1)
Conditions of standardization were more difficult to obtain for EVG
and technical adjustments are required to analyze data.
BRU IC50 obtained for DTG and RAL were similar to that reported in
previous studies leading to the validation of our results.
DTG IC50 obtained for 10 isolates ranged from 5,81.10
-3nM to 3,30nM
with a mean value at 0,911nM, and was 2,09nM for BRU. IC50 for RAL
were scattered over a range extending from 1,0.10-2nM to 3,22nM
(N=11), the mean was 1,44nM and IC50 for BRU was 2,07nM.
Preliminary results for EVG on 6 isolates showed a mean IC50 of
3,97nM. The large majority of HIV-1/O IC50 were lower than BRU IC50,
but a few strains have higher IC50 (DTG : N=2 ; RAL : N=5) always
under a fold change of 2.
Discussion / Conclusion
Natural susceptibility to DTG and RAL for HIV-1/O does not differ from
HIV-1/M, as IC50 averages are not higher than HIV-1/M IC50 (BRU).
Further investigations are in progress to complete these preliminary
results. Phenotypic results have to be compared to nucleotidic
sequence of each isolate to determine if the IC50 ranges are linked to a
specific natural polymorphism of the HIV-1/O integrase gene.
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IC50 (nM)
DTG RAL EVG
BCF001 A 0,427 * 0,01
BCF111 A * 2,83 *
BCF008 A * 0,024 *
BCF113 A 0,170 0,010 2,88
BCF101 A 2,65 2,74 *
BCF112 A * * 0,043
YBF18 A 0,081 0,3228 *
MVP5180 B 0,18 0,65 0,20
BCF006 B 1,88 0,742 *
BCF057 B 0,253 3,22 *
BCF010 C 0,11 3,07 *
BCF011 DIV 0,0581 0,664 0,66
BCF005 DIV 3,30 2,45 0,94
BRU HIV-1/M 2,09 2,07 *
BRU litterature values 1,86(3) 2,17(3) 0,4(4)
IC50 mean values 0,91 1,44 3,97
* technical adjustment required
Underlined values : IC50 higher than for BRU strain
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B,C: 100 µl of cell suspension at 2.106 cells/ml previously infected  
with viral supernatant  added with 100µL of drug solutions
D : 100 µL of cell suspension at 2.106 cellules/ml previously 
infected with diluted viral supernatant  (1/10 or 1/100)
«Negative control» : 100µL cell suspension at 2.106 cells/mL 
added with 100 µL of media
E : « drug toxicity control » : 100µL cell suspension at 
2.106cells/mL added with 100µL of drug solutions
Table 1 : IC50 results for the 3 drugs DTG, RAL and EVG
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Fig.1 : Phenotypic assay technical conditions
Thirteen clinical isolates representative of the intra-group O genetic
diversity (7 clade A, 3 clade B, 1 clade C, 2 divergent) and 1 lab
reference strain of HIV-1/M (BRU, susceptible to II) were studied.
A 3 days-long phenotypic assay was carried out by expanding each
isolate on peripheral blood mononuclear cells from healthy donors, in
presence of increasing concentrations of II ranging from 0 nm to 2 000
nm (Fig1). Replication was measured by viral load using a specific HIV-
1/O qRT-PCR [2]. IC50 values were calculating from the linear equation
between the viral load diminution and the increasing concentrations of
drugs. The assay was standardized on each strain growth during the test
and the incubation time was adjusted if necessary to 2 days or 4 days.
HIV-1 genetic diversity leads to a classification into 4 groups :
group M, responsible for the pandemic situation, group O (HIV-
1/O) endemic in Cameroon , group N and P more rare.
It has been showed that HIV-1/O has a natural high genetic
polymorphism that may have serious outcomes on antiretroviral
treatment response [1]. The more recent drugs, such as integrase
inhibitors (II) including Raltegravir (RAL), Elvitegravir (EVG) and
Dolutegravir (DTG), could be a reliable alternative for therapy
management in patients infected with these viruses. Yet few data
are available regarding the susceptibility of these viruses to II and
only refer to clinical case report or some in vitro studies on
restricted numbers of strains.
